Trizivir / Abacavir sulfate, lamivudine, and zidovudine
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Triumeq / Abacavir/dolutegravir/lamivudine
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tymlos / Abaloparatide
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tudorza Pressair / Aclidinium bromide
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Uroxatral / Alfuzosin hcl
Monitoring guidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Praluent / Alirocumab
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tekturna / Aliskiren hemifumarate
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tekturna HCT / Aliskiren hemifumarate and hydrochlorothiazide
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Oseni / Alogliptin and pioglitazone
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Letairis / Ambrisentan
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Norvasc / Amlodipine besylate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Azor / Amlodipine besylate and olmesartan medoxomil
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Exforge / Amlodipine besylate and valsartan
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Exforge HCT / Amlodipine valsartan and hydrochlorothiazide
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Saphnelo / Anifrolumab-fnia
Pharmacokinetics only · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Erleada / Apalutamide
Pharmacokinetics only · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Eliquis / Apixaban
Dose or interval change · Serum creatinine (mg/dL), age (years) and weight (kg)
Local official-label summary. Read the exact source scope and cautions.
Otezla / apremilast IR / Apremilast
Dose or interval change · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
Aponvie / Aprepitant
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Emend / Aprepitant
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Trisenox / Arsenic trioxide
Monitoring guidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Scemblix / Asciminib
No adjustment within stated limits · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Secuado / Asenapine
No adjustment within stated limits · GFR/eGFR in mL/min as reported by the source
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Reyataz / Atazanavir
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Evotaz / Atazanavir and cobicistat
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tenormin Tablets / Atenolol
Dose or interval change · CrCl normalized to 1.73 m2, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Tecentriq / Atezolizumab
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tecentriq Hybreza / Atezolizumab and hyaluronidase-tqjs
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Doptelet / Avatrombopag maleate
Evidence gap · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Bavencio / Avelumab
Pharmacokinetics only · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Edarbi / Azilsartan kamedoxomil
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Edarbyclor / Azilsartan kamedoxomil and chlorthalidone
No adjustment within stated limits · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Olumiant / Baricitinib
Dose or interval change · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
Benlysta / Belimumab
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Welireg / Belzutifan
Monitoring guidance · MDRD eGFR, mL/min as printed in this label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Fasenra / Benralizumab
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Generic names and brands can lead to different formulations. Select the matching route and release type.
Renal tables retain their indication, units and dialysis assumptions. Do not combine doses and intervals from different protocols.
Read source qualifications, monitoring and interactions. A missing dose or absent result does not mean no adjustment.
See all 26 A-Z review statuses and remaining work | Current evidence additions and verification results
1215 product/formulation records and 1125 selected RX summaries are local. These are selected renal summaries, not complete prescribing monographs. Coverage and independent clinical review remain incomplete.
Review coverage details